Article
Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study.
Investigational new drugs - 1 Apr 2018
Fujiwara Yutaka, Yamazaki Naoya, Kiyohara Yoshio, Yoshikawa Shusuke, Yamamoto Noboru, Tsutsumida Arata, Nokihara Hiroshi, Namikawa Kenjiro, Mukaiyama Akihira, Zhang Fanghong, Tamura Tomohide
Abstract excerpt
Background Dabrafenib is a BRAF inhibitor that has demonstrated clinical activity with a good tolerability profile in patients with BRAF V600E mutated metastatic melanoma. This study evaluated the safety and tolerability, pharmacokinetics and preliminary efficacy of dabrafenib in Japanese patients. Methods This phase I, open-label, dose escalation study was conducted in 12 Japanese patients with BRAF V600...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.